Latest News

Directorate Change

18 June 2020

Tiziana Life Sciences plc announces Gregor MacRae is standing down as a director of the Company with immediate effect.

Read more

Final Results for the Year Ended 31 December 2019

18 June 2020

Tiziana Life Sciences PLC, today announces its financial results for the year ended 31 December 2019.

Read more

Extension of At the Market Sales Agreement

12 June 2020

Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the agreement of an extension to the current At the Market Sales Agreement with ThinkEquity, a division of Fordham Financial Management, Inc.

As previously announced on 15 April 2020, Tiziana Life Sciences...

Read more

Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease

04 June 2020

TLSA Chairman of the Company’s Scientific Advisory Board, Dr. Howard Weiner, has received a competitive research grant from the National Institutes of Health (NIH) to investigate nasal anti-CD3 for the treatment of Alzheimer’s disease

Read more

Correction - Exercise of Warrants and Issue of Equity and Total Voting Rights

02 June 2020

The announcement (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,498,685 new ordinary shares will be issued yielding £710,843 in cash proceeds, the announcement should have stated the number of shares to be issued is...

Read more

Exercise of Warrants and Issue of Equity and Total Voting Rights

02 June 2020

London, New York, 2 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...

Read more

Page 2 of 15 Previous Next